Cantor Fitzgerald Forecasts Alumis FY2025 Earnings

Alumis Inc. (NASDAQ:ALMS) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for Alumis in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings per share of ($4.13) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.15) per share.

Other analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $26.00 price objective on shares of Alumis in a research report on Monday, January 6th. Robert W. Baird assumed coverage on shares of Alumis in a report on Thursday, October 31st. They set an “outperform” rating and a $25.00 price target for the company. Finally, Baird R W raised shares of Alumis to a “strong-buy” rating in a report on Thursday, October 31st. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $26.83.

Alumis Price Performance

Shares of ALMS stock opened at $6.78 on Thursday. The firm’s 50-day moving average is $8.43. Alumis has a 1-year low of $6.75 and a 1-year high of $13.53.

Institutional Trading of Alumis

A number of hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. bought a new position in shares of Alumis in the 3rd quarter worth approximately $191,000. Barclays PLC purchased a new stake in Alumis in the 3rd quarter worth approximately $197,000. Geode Capital Management LLC bought a new stake in Alumis during the 3rd quarter worth approximately $3,266,000. State Street Corp purchased a new position in Alumis during the third quarter valued at approximately $866,000. Finally, Stifel Financial Corp bought a new position in shares of Alumis in the third quarter worth approximately $931,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.